USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
VIROGENICS, INC.
Address:
PO BOX 2702
DEL MAR, CA 92014-
Phone:
N/A
URL:
N/A
EIN:
142157802
DUNS:
146101196
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,797,997.00 6
SBIR Phase II $2,309,520.00 1
STTR Phase I $599,936.00 1

Award List:

Lentiviral Vector Gene Therapy for CD45 Deliver

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$748,800.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by the applicant): The overall goal of this project is to address the need for an effective therapy for patients with severe combined immunodeficiency due to loss of CD45 function. CD45 deficiency is one of a group of genetic diseases that results in severe combined… More

FIV Vectors for the Treatment of Hemophilia A

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous FVIII protein infusions, either prophylacticly or during bleeding episodes. Prophylactic treatment, however, is problematic due to limited availability, high costs and concerns for… More

Non-Integrating FIV Vectors for HIV Vaccines

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$600,002.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The diagnosis of 15,000 new cases of HIV infections every day demonstrates the pressing need for a prophylactic HIV vaccine to prevent further spread of the pandemic. Some of the most encouraging results have been achieved with viral vector-based vaccines coding… More

Hemophilia A: Intrathymic Delivery for Tolerance and Longterm Expression of FVIII

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$149,881.00
Agency:
HHS
Principal Investigator:
William C. Raschke
Abstract:
DESCRIPTION (provided by applicant): The current standard of care for hemophilia A is treatment with intravenous human factor VIII (hFVIII) protein infusions, either prophylactically or during bleeding episodes. A major disadvantage for both prophylactic a nd on- demand FVIII protein infusions is… More

A Novel Immune Modulator/ Adjuvant for HIV Vaccines

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$599,314.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): During the past two decades of HIV vaccine development, a wide variety of AIDS vaccine strategies have been explored. Among the many tested, DNA and viral vector-based vaccines that activate cellular immune responses ha ve shown some promise despite their… More

FIV Vectors for the Treatment of Hemophilia A

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$2,309,520.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Although several labs including ours have demonstrated the feasibility of gene therapy for hemophilia A in animal models, long-term expression of the transgene at therapeutic levels was not observed in the clinic. The l ack of sufficient expression levels Factor… More

Modulation of the Innate Immune System by Fisetin for the Treatment of AD

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$599,936.00
Agency:
HHS
Principal Investigator:
Pamela A. Maher – 858-453-4100
Research Institution:
SALK INSTITUTE FOR BIOLOGICAL STUDIES
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): An increasing variety of diseases are being shown to be due to immunological processes, including diabetes, and now Alzheimer's disease (AD). AD is the most prevalent age-associated disease and growing evidence suggeststhat aspects of the innate immune… More

siRNA Modulation of the Immune Response

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
William C. Raschke – 858-775-0453
Abstract:
DESCRIPTION (provided by applicant): A major goal expressed by NIAID and other agencies charged with development of the U.S. biodefense research strategy is a broad spectrum activity that mitigates catastrophic biothreats across a wide spectrum of agents.Such therapeutic activities have been… More